Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
| Revenue (TTM) | $1.11B |
| Gross Profit (TTM) | $710.47M |
| EBITDA | $166.63M |
| Operating Margin | 9.87% |
| Return on Equity | 46.00% |
| Return on Assets | 10.90% |
| Revenue/Share (TTM) | $8.72 |
| Book Value | $3.24 |
| Price-to-Book | 12.66 |
| Price-to-Sales (TTM) | 4.75 |
| EV/Revenue | 4.816 |
| EV/EBITDA | 29.55 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 60.90% |
| Shares Outstanding | $128.02M |
| Float | $83.22M |
| % Insiders | 11.37% |
| % Institutions | 110.43% |
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share a year ago.
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Apellis (NASDAQ: APLS) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Biogen.
